Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 5
Submit an article Journal homepage
883
Views
13
CrossRef citations to date
0
Altmetric
Letter to the Editor

Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin

Brian T. HillDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence[email protected]
,
Raymond R. TubbsDepartment of Molecular Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH, USA
&
Mitchell R. SmithDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Pages 1552-1553 | Received 16 Jan 2014, Accepted 30 Mar 2014, Published online: 09 Apr 2014

References

  • Bartlett NL, Sharman JP, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphoma. Blood 2013;120(Suppl. 1): Abstract 848.
  • Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol 2013;53:866–877.
  • Brentuximab vedotin [package insert]. Bothell, WA: Seattle Genetics; 2013.
  • Han TH, Grove LE, Lynch CM. Effect of renal impairment on the pharmacokinetics of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. Presented at American Society of Pharmacology and Therapeutics Annual Meeting, 5–9 March 2013, Indianapolis, IN, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.